Suvorexant is a medication used to treat insomnia. (difficulty falling asleep or staying asleep). Suvorexant belongs to a family of drugs known as orexin receptor antagonists. It works by inhibiting the effect of a naturally occurring chemical in the brain that induces wakefulness.
🛒 How to order this item?
Indications
Suvorexant is used to treat insomnia, which is characterized by problems falling asleep and staying asleep.
Suvorexant is a highly selective orexin receptor OX1R and OX2R antagonist. Suvorexant's therapeutic effect on insomnia is thought to be due to orexin receptor antagonism. The orexin neuropeptide signaling pathway is a key factor in promoting alertness. Wake drive is considered to be suppressed by blocking the binding of the wake-promoting neuropeptides orexin A and orexin B to the receptors OX1R and OX2R.
Adult Dose:
Child Dose:
Renal Dose:
CNS Active Drug: When a single 40 mg dose of Suvorexant was co-administered with a single 0.7 g / kg alcohol dose, an additive effect on psychomotor performance was observed. Suvorexant does not affect alcohol concentration and alcohol does not affect Suvorexant concentration.
Effects of other medications on Suvorexant: Strong (eg ketoconazole or itraconazole) and moderate CYP3A inhibitors (eg diltiazem) significantly increase exposure to Suvorexant. Strong CYP3A inducers (eg, rifampicin) significantly reduce exposure to Suvorexant.
Effect of Suvorexant on other drugs: Suvorexant is unlikely to have a clinically significant inhibitory effect on human CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or CYP2D6. Long-term administration of Suvorexant is unlikely to induce the metabolism of drugs metabolized by the major CYP isoforms.
In individuals with narcolepsy, do not use it.
Pregnancy Classification C. In pregnant women, there are no appropriate and well-controlled trials. Suvorexant should only be used while pregnant if the possible benefit outweighs the danger to the fetus.
Daytime somnolence: Risk of poor alertness and motor coordination, including impaired driving; risk rises with dose; warn patients taking 20 mg not to drive or do anything else that requires complete mental alertness the next day.
Evaluation for co-morbid disorders is required: If sleeplessness continues after 7 to 10 days of therapy, reevaluate.
Store in a dry and cool place, protect from light & keep away from children.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.